Clear Cell Adenocarcinoma: Causes, Symptoms, and Treatment

Clear cell adenocarcinoma is a distinctive cancer subtype defined by cells with abundant, glassy cytoplasm that can arise in several organs, most commonly the ovary, uterine cervix, vagina, and, less frequently, the urinary bladder and urethra. Its causes vary by location: ovarian cases are strongly linked to endometriosis, cervical and vaginal cases have a historic connection to prenatal diethylstilbestrol (DES) exposure, and urinary tract cases remain poorly understood. The disease is rarer than many other carcinoma subtypes but carries a reputation for resistance to standard platinum-based chemotherapy, which makes early detection and appropriate surgical management especially important.

What Makes Clear Cell Adenocarcinoma Different Under the Microscope

The name “clear cell” comes directly from the tumor’s appearance on a glass slide. When pathologists stain a tissue sample, the cancer cells show a glassy, almost empty-looking interior because their cytoplasm is packed with glycogen and lipid that washes out during processing. The cells arrange themselves in several recognizable patterns: solid sheets, glandular tubes, cystic spaces, or papillary fingers of tissue projecting into a cavity. A hallmark feature is the “hobnail cell,” where the rounded nucleus bulges beyond the cell surface like a nail head poking through a shoe sole.¹ Small, round, glassy globules called hyaline bodies are also scattered throughout the tumor in many cases.²

These microscopic features look strikingly similar regardless of where the tumor occurs. Clear cell adenocarcinoma in the bladder or urethra closely resembles the version found in the ovary or cervix, which is why pathologists historically described all of them as having “Müllerian” features, referring to the embryonic tissue that gives rise to the female reproductive tract.³ That shared appearance creates a diagnostic challenge when the cancer has spread: a clear cell tumor found in the abdomen could have originated in the ovary, the kidney, the peritoneum, or even the bladder, and telling these apart by morphology alone is unreliable.⁴

Causes and Risk Factors

The driving forces behind clear cell adenocarcinoma depend heavily on where the tumor forms. For ovarian clear cell carcinoma, the strongest known risk factor is endometriosis, a condition in which tissue resembling the uterine lining grows outside the uterus. Endometriosis is considered a direct precursor: researchers have traced the cellular lineage from normal uterine lining to endometriotic tissue to full-blown ovarian clear cell carcinoma, finding shared mutations at every step.⁵ The mutations accumulate over time: endometriotic cells first acquire changes in genes like ARID1A and PIK3CA, and when enough of these pile up, the cells cross the threshold into cancer.

For cervical and vaginal clear cell adenocarcinoma, the best-documented cause is prenatal exposure to DES, a synthetic estrogen prescribed to millions of pregnant women between the late 1940s and 1971 to prevent miscarriage. In 1971, a cluster of young women with vaginal clear cell adenocarcinoma was traced back to their mothers’ DES use during pregnancy, prompting an abrupt end to the drug’s use in obstetrics.⁶ A long-running follow-up with the largest dataset available confirmed the connection, showing elevated risk persisting decades after exposure.⁷ That said, vaginal and cervical clear cell adenocarcinomas also occur in women with no DES exposure at all, so other factors remain under investigation.

Clear cell adenocarcinoma of the urinary bladder is much rarer and has no single clearly established cause. It disproportionately affects women, typically presenting around age 60, and its origin is debated. Some researchers believe these tumors arise from remnants of Müllerian-type tissue in the bladder wall, while others suspect a connection to chronic inflammation or structural abnormalities like urethral diverticula.⁸

The Molecular Landscape

Regardless of where it forms, ovarian clear cell carcinoma has a recognizable genetic signature dominated by two genes: ARID1A and PIK3CA. ARID1A normally acts as a tumor suppressor, helping control which genes get turned on or off. When both copies of ARID1A are knocked out by mutations, cells lose a critical brake on growth. PIK3CA, by contrast, is a growth-promoting gene. Activating mutations in PIK3CA push cells to divide faster. Animal studies have shown that losing ARID1A alone is not enough to form tumors, but combining ARID1A loss with PIK3CA activation reliably produces tumors that look and behave like human ovarian clear cell carcinoma.⁹

In human tumors, PIK3CA mutations are found in roughly 40% of ovarian clear cell carcinomas, and loss of ARID1A protein expression occurs in close to half of cases. Tumors that have lost ARID1A are more likely to also carry a PIK3CA mutation and to have endometriosis nearby, supporting the idea that these two genetic hits happen early in the transformation from benign endometriotic tissue to cancer.¹⁰ Other driver genes identified in the endometriosis-to-cancer pathway include ATM, NRAS, and MET, along with dysregulated small RNA molecules.¹¹

Symptoms and How the Cancer Is Found

Because clear cell adenocarcinoma can develop in several different organs, the symptoms that lead to diagnosis vary considerably. Ovarian clear cell carcinoma often presents much like other ovarian cancers: bloating, pelvic pain, difficulty eating, or a feeling of fullness. Many ovarian cases are found incidentally during imaging or surgery for a suspected ovarian cyst or endometrioma. On imaging, ovarian clear cell tumors tend to appear as large, partly cystic masses with a solid component projecting into the cyst. CT and MRI can help distinguish early from advanced disease, with certain imaging features like bilateral involvement, fluid in the abdomen, and associated blood clots suggesting a more advanced stage.¹²

Vaginal and cervical clear cell adenocarcinoma typically presents with irregular vaginal bleeding, which can persist for years before diagnosis in some patients.¹³ In the bladder and urethra, the most common presentation is blood in the urine, painful urination, or symptoms that mimic a urinary tract infection that does not respond to antibiotics.¹ Urethral cases are particularly aggressive; in one study of five patients, all were women with a median age of 62, all progressed to distant spread, and the lungs were the most common site of metastasis.¹⁴

Diagnosis and the Role of Biomarkers

Confirming a diagnosis of clear cell adenocarcinoma requires a tissue biopsy examined under a microscope. Because several cancers can look similar, pathologists rely on a panel of immunohistochemical stains to pin down the subtype. One particularly useful marker is HNF-1β (hepatocyte nuclear factor-1β), a protein that is consistently expressed in clear cell adenocarcinomas but rarely in other tumor types. In a study of ovarian cancers, all pure clear cell carcinomas stained positive for HNF-1β, while none of the high-grade serous carcinomas did.¹⁵

HNF-1β is also useful for identifying clear cell adenocarcinoma in the urinary tract. In one series, all 18 clear cell adenocarcinomas of the bladder and urethra showed strong nuclear staining for HNF-1β, while staining was absent or weak in almost all conventional bladder adenocarcinomas and urothelial carcinomas tested alongside them.¹⁶ In cervical carcinomas, HNF-1β expression is largely restricted to adenocarcinomas and can be combined with squamous cell markers like p63 and D2-40 to sort out difficult cases.¹⁷

Surgical Treatment

Surgery is the cornerstone of treatment for clear cell adenocarcinoma when the tumor has not widely spread. For ovarian clear cell carcinoma, the standard approach is the same as for other ovarian cancers: removal of the uterus, both ovaries and fallopian tubes, the omentum (a fatty apron hanging from the colon), and sampling of lymph nodes for staging purposes. Staging is important because cancer that appears confined to the ovary at the time of surgery sometimes turns out to have spread microscopically. In one large series of patients with apparent ovary-confined disease who underwent thorough lymph node removal, about one in five was upstaged to a higher stage on final pathology review.¹⁸

The question of how extensive staging surgery needs to be remains debated. A separate analysis of patients with clear cell and endometrioid ovarian cancers that appeared stage I at surgery found the likelihood of occult extraovarian disease to be very low, leading those authors to suggest comprehensive staging may provide no added benefit in those particular cases.¹⁹ This disagreement in the literature reflects a real tension between doing more to catch rare upstaging events and sparing patients the morbidity of aggressive surgery when most will not benefit from it.

For urethral clear cell adenocarcinoma, surgery often needs to be radical because the tumors tend to invade nearby structures like the vagina early on.¹⁴

Chemotherapy and the Platinum-Resistance Problem

One of the defining clinical challenges of ovarian clear cell carcinoma is its resistance to standard platinum-based chemotherapy. Most other types of ovarian cancer respond well, at least initially, to combinations of carboplatin and paclitaxel. Clear cell tumors often do not. Several mechanisms contribute to this resistance, including low cell-proliferation rates (slow-dividing cells are harder for chemotherapy to kill), increased ability to repair DNA damage inflicted by platinum drugs, and enhanced detoxification of the drugs within tumor cells.²⁰

When platinum-based treatment fails, clinicians look for alternatives. A study of patients with platinum-resistant ovarian clear cell carcinoma found that gemcitabine as the first subsequent drug produced better overall survival than other single agents, with a median survival of about 15 months compared to 11 months. Adding bevacizumab, a drug that blocks the growth of new blood vessels feeding the tumor, extended the time before treatment failure from under three months to over six months.²¹ These numbers are modest improvements, underscoring how difficult this cancer can be to treat once it resists first-line therapy.

Targeted Therapy and Immunotherapy

The molecular profile of clear cell adenocarcinoma offers potential inroads for targeted therapy. Because the PIK3CA pathway is frequently activated, drugs targeting this signaling cascade are being explored. Meanwhile, clear cell renal cell carcinoma (a related but genetically distinct cancer arising in the kidney) has seen major treatment advances with combinations of antiangiogenic drugs and immune checkpoint inhibitors. Multiple large randomized trials have tested drugs like nivolumab and pembrolizumab, which block the PD-1/PD-L1 interaction that cancers exploit to hide from the immune system, in combination with drugs that starve tumors of their blood supply.²² These combinations have become standard treatment for advanced kidney clear cell carcinoma.²³

The success of immunotherapy in kidney clear cell carcinoma has prompted interest in applying similar strategies to gynecologic clear cell tumors, though evidence there is less mature. Researchers have also identified novel vulnerabilities: for instance, lab studies showed that inhibiting an enzyme involved in amino acid production (PHGDH, critical for serine biosynthesis) could suppress tumor growth in kidney clear cell carcinoma cells that had developed resistance to other targeted drugs, with significant results in animal models.²⁴ This kind of work is still far from the clinic but illustrates how understanding the biology of clear cell tumors opens doors for new drug strategies.

The Blood Clot Problem

A feature that sets ovarian clear cell carcinoma apart from other ovarian cancers is its unusually high risk of blood clots. A systematic review and meta-analysis pooling data across studies found that roughly one in five patients with ovarian clear cell carcinoma develops a venous thromboembolism, either a deep-vein thrombosis or a pulmonary embolism.²⁵ By comparison, the rate in other epithelial ovarian cancers is much lower. One study documented blood clots in about 27% of clear cell carcinoma patients versus roughly 7% in other ovarian cancer subtypes, with pulmonary embolism occurring in about 14% of the clear cell group.²⁶

This is not just a laboratory curiosity. Blood clots can be life-threatening, and the presence of thromboembolism on imaging is itself associated with more advanced disease.¹² Clinicians managing ovarian clear cell carcinoma are generally vigilant about clot prevention, but the elevated risk means patients should be aware that swelling in one leg, sudden shortness of breath, or chest pain after diagnosis warrants urgent medical attention.²⁷

Prognosis by Stage

Like most cancers, outcomes for clear cell adenocarcinoma depend enormously on how far the disease has spread at diagnosis. Ovarian clear cell carcinoma caught at stage I (confined to one or both ovaries) carries an excellent prognosis, with three-year overall survival around 90%. Within stage I, though, there is a meaningful split: patients with stage IA disease (tumor completely inside one ovary, capsule intact) had better outcomes than those with stage IC disease where tumor was found on the ovarian surface. Three-year overall survival dropped to about 72% when the tumor had broken through the surface, compared to over 96% when the capsule had simply ruptured during surgery but the surface was clean.²⁸

For advanced-stage disease, the picture is grimmer. Three-year overall survival for stage III patients was about 53%, falling to roughly 30% for stage IV. And when the cancer recurs, the pattern of recurrence matters: patients whose cancer came back in a single spot had a median post-recurrence survival of over four years, while those with recurrence at multiple sites survived a median of under 14 months.²⁹ This stark difference means surveillance after treatment is geared toward catching recurrence early and in as localized a form as possible.

Who Gets It and Why the Rates Differ Around the World

Ovarian clear cell carcinoma is not evenly distributed across populations. It is substantially more common among women of Asian and Pacific Islander descent than among white or Black women. Data from the United States show that about 14.5% of ovarian cancers in Asian and Pacific Islander women are the clear cell subtype, compared to about 6.6% in white women and 4.3% in Black women.³⁰ The disparity holds up when you look at individual ethnicities: Chinese, Filipino, and Japanese women all had higher incidence rates of clear cell ovarian cancer than non-Hispanic white women.³¹

The reason for this ethnic disparity is not fully explained. Differences in endometriosis prevalence, genetic susceptibility, environmental exposures, and reproductive patterns have all been proposed as contributors. The fact that the elevated risk persists regardless of whether the woman was born in Asia or in the United States argues against purely environmental explanations and points toward genetic or epigenetic factors playing a role.³⁰

Fertility-Preserving Approaches

Because clear cell adenocarcinoma of the cervix and vagina sometimes strikes young women, the question of preserving fertility is a real and pressing one. Standard treatment for many gynecologic cancers involves removing the uterus and ovaries, which eliminates the possibility of future pregnancy. For early-stage cervical clear cell adenocarcinoma, limited data suggest that fertility-sparing surgery can be feasible. In one series, patients with early-stage cervical clear cell adenocarcinoma who underwent conservative treatment had no recurrences, and their overall outcomes were comparable to patients with other types of cervical adenocarcinoma.³²

Innovative surgical approaches have pushed the boundaries further. One reported case involved a young woman with early-stage vaginal clear cell adenocarcinoma who underwent a radical vaginectomy with reconstruction using a tissue flap from the abdomen, preserving her uterus and avoiding chemotherapy or radiation entirely.³³ Another case involved a six-year-old girl with cervical clear cell adenocarcinoma treated with local excision under a hysteroscope and chemotherapy chosen to minimize damage to her still-undeveloped ovarian follicles, because dormant follicles are less sensitive to the toxic effects of chemotherapy drugs.³⁴ These remain individual case reports rather than standard protocols, but they illustrate a growing interest in tailoring treatment to preserve quality of life without sacrificing cancer control in carefully selected patients.

Clear Cell Renal Cell Carcinoma and Why It Matters Separately

Readers looking up “clear cell adenocarcinoma” will also encounter clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer. Despite sharing the “clear cell” descriptor, kidney clear cell carcinoma is a genetically and clinically distinct disease from the gynecologic clear cell tumors discussed above. It arises from the lining of the kidney’s tiny filtering tubes and is driven by different mutations, most notably loss of the VHL gene rather than ARID1A. Its treatment has evolved rapidly, with combinations of antiangiogenic drugs and immune checkpoint inhibitors becoming standard first-line therapy for advanced disease.²²

The overlap in names can lead to confusion, especially when searching for treatment information. A drug regimen that is standard of care for kidney clear cell carcinoma may have little or no evidence supporting its use in ovarian or cervical clear cell adenocarcinoma, and vice versa. The distinction matters because these cancers behave differently, respond to different drugs, and carry different prognoses. When evaluating treatment options, it is worth confirming which organ the “clear cell” cancer arose from, because the management pathways diverge significantly.